As of 2024-12-13, the Relative Valuation of Pacific Biosciences of California Inc (PACB) is (46.50) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.04 USD, the upside of Pacific Biosciences of California Inc based on Relative Valuation is -2373.7%.
The range of the Relative Valuation is (43.16) - (47.88) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 29.8x - 33.7x | 32.7x |
| Forward P/E multiples | 30.0x - 33.3x | 31.9x |
| Fair Price | (43.16) - (47.88) | (46.50) |
| Upside | -2210.4% - -2441.3% | -2373.7% |
| Date | P/E |
| 2024-12-03 | -1.27 |
| 2024-12-02 | -1.34 |
| 2024-11-29 | -1.33 |
| 2024-11-27 | -1.22 |
| 2024-11-26 | -1.23 |
| 2024-11-25 | -1.29 |
| 2024-11-22 | -1.25 |
| 2024-11-21 | -1.23 |
| 2024-11-20 | -1.19 |
| 2024-11-19 | -1.19 |
| 2024-11-18 | -1.09 |
| 2024-11-15 | -1.11 |
| 2024-11-14 | -1.29 |
| 2024-11-13 | -1.38 |
| 2024-11-12 | -1.53 |
| 2024-11-11 | -1.71 |
| 2024-11-08 | -1.60 |
| 2024-11-07 | -1.70 |
| 2024-11-06 | -1.84 |
| 2024-11-05 | -1.77 |
| 2024-11-04 | -1.74 |
| 2024-11-01 | -1.69 |
| 2024-10-31 | -1.51 |
| 2024-10-30 | -1.50 |
| 2024-10-29 | -1.43 |
| 2024-10-28 | -1.28 |
| 2024-10-25 | -1.23 |
| 2024-10-24 | -1.19 |
| 2024-10-23 | -1.22 |
| 2024-10-22 | -1.25 |
| 2024-10-21 | -1.28 |
| 2024-10-18 | -1.38 |
| 2024-10-17 | -1.32 |
| 2024-10-16 | -1.43 |
| 2024-10-15 | -1.46 |
| 2024-10-14 | -1.42 |
| 2024-10-11 | -1.38 |
| 2024-10-10 | -1.08 |
| 2024-10-09 | -1.12 |
| 2024-10-08 | -1.17 |
| 2024-10-07 | -1.18 |
| 2024-10-04 | -1.19 |
| 2024-10-03 | -1.13 |
| 2024-10-02 | -1.14 |
| 2024-10-01 | -1.13 |
| 2024-09-30 | -1.18 |
| 2024-09-27 | -1.22 |
| 2024-09-26 | -1.21 |
| 2024-09-25 | -1.10 |
| 2024-09-24 | -1.20 |